These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26983637

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
    Timmermand OV, Ulmert D, Evans-Axelsson S, Pettersson K, Bjartell A, Lilja H, Strand SE, Tran TA.
    EJNMMI Res; 2014 Dec; 4(1):51. PubMed ID: 26116115
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.
    J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
    [Abstract] [Full Text] [Related]

  • 11. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ.
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 18. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 19. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
    Bicak M, Lückerath K, Kalidindi T, Phelps ME, Strand SE, Morris MJ, Radu CG, Damoiseaux R, Peltola MT, Peekhaus N, Ho A, Veach D, Malmborg Hager AC, Larson SM, Lilja H, McDevitt MR, Klein RJ, Ulmert D.
    Proc Natl Acad Sci U S A; 2020 Jun 30; 117(26):15172-15181. PubMed ID: 32532924
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.